BIOTRONIK Neuro Launches Embrace One® Proactive Intelligence, a Proprietary AI Capability that Identifies Emerging Support Needs in SCS Patients

BIOTRONIK Neuro Launches Embrace One® Proactive Intelligence, a Proprietary AI Capability that Identifies Emerging Support Needs in SCS Patients

Data presented at ASPN demonstrate the AI model's ability to identify patients who may benefit from support, often before they recognize a problem themselves¹

MIAMI, July 20, 2026 /PRNewswire/ -- BIOTRONIK Neuro today announced the launch of Embrace One® Proactive Intelligence, a proprietary AI capability that advances proactive care for patients implanted with the Prospera® Spinal Cord Stimulation (SCS) System. BIOTRONIK Neuro collects more than 200 data points per patient daily through automatic, objective remote monitoring, and the new AI capability analyzes this data to identify early signals that may indicate a patient could benefit from additional support or therapy optimization.

The AI model does not make clinical decisions or adjust therapy. Instead, it provides additional insight to BIOTRONIK Neuro's Embrace One Care Team—a dedicated group of clinical specialists who actively monitor patients and provide timely, personalized care between office visits—to help prioritize patient outreach and follow-up support. Because Embrace One Proactive Intelligence uses data already collected through the Prospera system, it requires no additional effort from patients or healthcare providers.

New real-world data presented at the American Society of Pain and Neuroscience (ASPN) Annual Meeting demonstrated the AI model's ability to identify patients who may benefit from proactive outreach. In a prospective pilot study, the model identified 188 behavioral-pattern instances across 175 patients for review by the Embrace One Care Team. Patients responded to proactive outreach in 80.9% of cases. Overall, nearly 4 out of 5 cases resulted in targeted support from the Embrace One Care Team, including remote reprogramming, therapy optimization, and additional patient education.¹

"This level of support gives me great peace of mind," said David Dickerson, MD, Endeavor Health, Chicago, IL. "One of the challenges in managing SCS therapy is that patients don't always recognize how subtle changes in their behavior may impact pain relief. Proactive Intelligence strengthens the Embrace One Care Team's ability to identify patients who may benefit from outreach, creating more opportunities to address issues proactively and connect patients with the support they need."

Historically, post-implant SCS management has relied on patients recognizing therapy issues and initiating follow-up care themselves. As the first and only SCS manufacturer to offer automatic, objective daily remote monitoring and remote programming, BIOTRONIK Neuro established a new standard for proactive SCS management that combines continuous passive monitoring with personalized support from the Embrace One Care Team.